Two weeks after his confirmation, new U.S. Food and Drug Administration Commissioner Scott Gottlieb was already hard at work looking to hire additional staff and addressing ways to prevent speculator pharma companies from jacking up prices on drugs for which there is no generic equivalent.
A moderate-intensity walking regimen may reduce symptoms of mild cognitive impairment that are linked to poor blood vessel health in the brain, a small study suggests.
Havas Group is expanding its capabilities and footprint in the important and burgeoning Indian market by adding Sorento to its roster of agencies.
The U.S. FDA Oncologic Drugs Advisory Committee recommended approval of Pfizer’s proposed epoetin alfa biosimilar across all indications.
U.S. deaths from Alzheimer’s disease rose by more than 50 percent from 1999 to 2014 – and rates are expected to continue to rise – reflecting the nation’s aging population and increasing life expectancy, American researchers said.
FDA Advisory Committee Recommends Approval of Endari from Emmaus Life Sciences for the Treatment of Sickle Cell Disease
Emmaus Life Sciences Inc. announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 10-to-3 that the overall Benefit-Risk profile of Endari for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.
June has the potential to be a make-or-break month for a number of biotech companies. At least 10 are facing critical decisions by the U.S. Food and Drug Administration (FDA).
The number of new drugs approved for sale in United States and Europe has bounced back in 2017, suggesting a marked slowdown in 2016 was an aberration.
Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
Merck announced that it has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer’s disease (AD).